drugset / Trial / NCT03255512

Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients

NCT03255512

Phase 1 Completed 41 enrolled Bayer Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is intended to investigate the pharmacodynamic drug-drug interaction as well as the safety and tolerability of isosorbite mononitrate and vericiguat in patients with stable coronary artery disease.

Timeline

Start
2017-08-17
Primary completion
2018-02-07
Completion
2018-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Isosorbide Mononitrate Other / unclassified 60 mg
Subject Vericiguat Other / unclassified 10 mg